menu

Reshaping LDL-C Management in Primary Hyperlipidemia with First-in-Class siRNA Therapy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Reshaping LDL-C Management in Primary Hyperlipidemia with First-in-Class siRNA Therapy

Details
Recommended

Overview

ReachMD Image
RestartResume

Why should clinicians choose this siRNA therapy that targets the liver for management of elevated LDL-C?

  • Sponsored by

  • Overview

    LEQVIO® (inclisiran) is a first-in-class small interfering RNA (siRNA) that treats low-density lipoprotein (LDL) cholesterol in patients with primary hyperlipidemia who have been unable to reach their recommended LDL-C goal with diet and statin therapy. LEQVIO is designed to selectively target the liver. To learn more about this MOA, join Dr Stephanie Saucier, Noninvasive Cardiologist from Hartford, Connecticut, and Dr Richard Wright, Clinical Cardiologist and Cardiovascular Pharmacologist from Santa Monica, California. 

    Dr. Saucier and Dr. Wright have been compensated for their time.

  • INDICATIONS

    LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

  • IMPORTANT SAFETY INFORMATION

    Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

    Please click here for LEQVIO full Prescribing Information.

    11/23      314000

Schedule28 Feb 2024